Tempus contends the transferred data was de-identified, but plaintiffs argue that genetic information is inherently identifiable regardless of what identifying details are removed. The scope of downstream recipients and the specific terms of the licensing agreements remain partially unclear, though the complaints name pharmaceutical and biotech companies as recipients. Tempus reported revenue growth exceeding 83% year-over-year in 2025, with plaintiffs attributing significant portions of that growth to commercializing the Ambry genetic data.
The litigation exposes substantial liability for healthcare platforms and life sciences vendors as data-sharing partnerships face public scrutiny. Attorneys should monitor how courts address whether genetic data can be meaningfully anonymized under state privacy statutes, and whether acquisition-related data transfers trigger consent requirements even when the original data collection predates the transaction. The case will likely influence how healthcare companies structure post-acquisition data integration and licensing arrangements.